Thousands of women with advanced breast cancer could be denied life-extending drugs because of the “unfair” way they are ...

June brought major breast cancer updates, and CURE is sharing the latest treatment combinations, biomarker-driven care and ...

Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows. A potential new first-line treatment option for patients ...

Enhertu is already approved for more advanced cases of HER2-positive breast cancer, as well as a string of other oncology indications, and made $3.75 billion in sales last year while adding ...

The 70-year-old former school principal said she had used some of herlife savings to pay for the drug Enhertu. Advertisement Advertise with NZME. Advertisement Advertise with NZME.

PITTSBURGH — Some 264,000 women will get a breast cancer diagnosis this year, with 50% to 60% of them having a type of cancer called HER2 low. That means the tumors have low levels of the HER2 ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the DESTINY-Breast03 trial, as well as several other indications, including HR ...

Erika Hamilton, MD, shares key insights from the 2025 ASCO Annual Meeting that are set to impact breast cancer treatment.

Lea Hughes, now 38, was 29 when she first noticed a small lump on her right breast, Daily Mail reports. Yet, when she brought ...

A mum from Banbury with breast cancer said a life-extending drug would be 'worth it', as a charity speaks out on the 'unfair' ...

At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial ...